Login | Register

Ruxolitinib Produces Durable Improvements In Patients With Myelofibrosis

ATLANTA - Ruxolitinib reduces splenomegaly and other symptoms commonly associated with myelofibrosis, and the results are maintained for at least two years, according to results released at the 54th American Society of Hematology Annual Meeting...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *